Ranked #3,293 of 8,699 institutional investors
Lynx1 Capital Management LP
Dorado, PR
$587M
US stock portfolio at live prices · today +$3.0M (+0.51%)
Live prices, last trade 11:28 AM ET
- Value at quarter end (Q3 2026)
- $646M
- Change from Q2 2026
- −$219.4M (−25.35%)
- Positions
- 28 · 6 new, 1 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$315M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesSTOK 18.1%CGEM 13.8%DTIL 3.43%KRRO 3.33%CCCC 3.19%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| STOK Stoke Therapeutics, Inc. | 3,896,169 | $106M | 18.1% | Reduced −4% |
| CGEM Cullinan Therapeutics, Inc. | 8,963,500 | $80.9M | 13.8% | Unchanged |
| DTIL Precision BioSciences, Inc. | 2,758,215 | $20.1M | 3.43% | Added +190% |
| KRRO Korro Bio, Inc. | 1,544,980 | $19.5M | 3.33% | Added +0% |
| CCCC C4 Therapeutics, Inc. | 7,530,915 | $18.7M | 3.19% | Added +3% |
| AGIO Agios Pharmaceuticals, Inc. | 472,606 | $13.5M | 2.29% | Reduced −86% |
| PASG Passage Bio, Inc. | 673,759 | $2.4M | 0.40% | Unchanged |
| NEUP Neuphoria Therapeutics Inc. | 875,328 | $2.1M | 0.35% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 278,606 | $1.3M | 0.21% | Added +56% |
| TCRX TScan Therapeutics, Inc. | 8,019,148 | $1.2M | 0.21% | Unchanged |
| KZIA Kazia Therapeutics Limited | 225,800 | $1.1M | 0.19% | New |
| PLRX Pliant Therapeutics, Inc. | 1,798,070 | $1.1M | 0.18% | Unchanged |
| HOWL Werewolf Therapeutics, Inc. | 657,786 | $618K | 0.11% | Unchanged |
| XNCR Xencor, Inc. | 18,194 | $612K | 0.10% | Unchanged |
| SRZN Surrozen, Inc. | 20,000 | $590K | 0.10% | New |
| DYN Dyne Therapeutics, Inc. | 25,000 | $398K | <0.1% | New |
| IMCR Immunocore Holdings plc | 14,300 | $381K | <0.1% | New |
| YARW Yarrow Bioscience, Inc. | 22,000 | $306K | <0.1% | New |
| DNLI Denali Therapeutics Inc. | 11,658 | $218K | <0.1% | Unchanged |
| PRME Prime Medicine, Inc. | 45,000 | $174K | <0.1% | New |
| ABSI Absci Corporation | 21,245 | $163K | <0.1% | Unchanged |
| BOLT Bolt Biotherapeutics, Inc. | 30,800 | $155K | <0.1% | Unchanged |
| TRAW Traws Pharma, Inc. | 559,470 | $120K | <0.1% | Unchanged |
| FHTX Foghorn Therapeutics Inc. | 61,588 | $107K | <0.1% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 10,100 | $68K | <0.1% | Unchanged |
| NUVB Nuvation Bio Inc. | 16,029 | $61K | <0.1% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 10,000 | $59K | <0.1% | Unchanged |
| IKT Inhibikase Therapeutics, Inc. | 584 | $763 | <0.1% | Reduced −97% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CGON CG Oncology, Inc. | 31,391 | $2.6M |